

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

August 22, 2014

(Date of Report - date of earliest event reported)

**Tekmira Pharmaceuticals Corporation**

(Exact Name of Registrant as Specified in Its Charter)

**British Columbia, Canada**

(State or Other Jurisdiction of  
Incorporation or Organization)

**001-34949**

(Commission File Number)

**98-0597776**

(I.R.S. Employer  
Identification No.)

**100-8900 Glenlyon Parkway**

**Burnaby, British Columbia, Canada**  
(Address of Principal Executive Offices)

**V5J 5J8**

(Zip Code)

**(604) 419-3200**

(Registrant's Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' Compensatory Arrangements of Certain Officers.**

On August 22, 2014, Kenneth Galbraith delivered to us notice of his resignation as a member of the Board of Directors of Tekmira Pharmaceuticals Corporation (the "Corporation"), effective immediately upon delivery. To the knowledge of the Corporation, Mr. Galbraith's resignation was not the result of any disagreement with the Corporation relating to the Corporation's operations, policies or practices. Mr. Galbraith had served as a member of the Board of Directors since January 2010.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 26, 2014

**TEKMIRA PHARMACEUTICALS CORPORATION**

By: /s/ Mark J. Murray  
Name: Mark J. Murray  
Title: President & Chief Executive Officer

